The distribution of protein kinase C (PKC) subspecies and their colocalization with neurotransmitters were examined in the rat striatum and substantia nigra (SN), using immunocytochemistry.
The (Y-and BI-PKC immunoreactivies were seen predominantly in the perikarya of the neurons in the striatum and SN. In contrast, the fill-and y-PKC immunoreactivities were abundant in both the perikarya and the neuropils in the striatum and only in the neuropils in the SN. From electron microscopic studies, the (Y-and fll-PKC immunoreactivities were seen adjacent to the plasma membrane, while the fill-PKC immunoreactivity was observed in the cytoplasm around the Golgi complex. The -/-PKC immunoreaction was dense throughout the cytoplasm. The double-staining and lesion studies revealed that the a-PKC-immunopositive neurons in the striatum were intrinsic cholinergic neurons, and that most of the a-PKC-immunoreactive neurons in the SN were dopaminergic neurons. The @I-PKC-immunoreactive neurons were intrinsic GABAergic neurons in the striatum. Moreover, most of the Bll-and y-PKC-immunoreactive neurons were medium-sized neurons projecting to the SN, and over 90% of GABAergic neurons in the caudate-putamen contained fill-PKC. The @II-PKC-immunoreactive neurons showed no r-PiiC immunoreactivity, and the -y-PKC-immunoreactive neurons were not fill-PKC immunoreactive.
These findings suggest that a-PKC is related to the function of the nigral dopaminergic and the striatal cholinergic neurons, and that the @I-PKC is involved in the function of the striatal intrinsic GABAergic neurons. The @II-and r-PKC may also modulate a specific neuronal function in the striatonigral system. Protein kinase C (PKC), a calcium-activated and phospholipiddependent protein kinase, has been considered to have a key role for cell-surface signal transduction (for reviews, see Nishizuka, 1984 Nishizuka, , 1986 Huang, 1990) . Recent molecular cloning studies revealed that PKC is a large family consisting of at least 7 subspecies (Nishizuka, 1988) . Early enzymological analysis revealed that PKC isolated from the rat brain can be resolved into 3 major fractions (type I, type II, and type III) by hydroxyapatite-column chromatography (Huang et al., 1986) , which correspond toy, PI + PII, and 01, respectively Ono et al., 1987) . The enzyme is widely distributed in various tissues and seems to be implicated in several physiological processes (Nishizuka, 1984 (Nishizuka, , 1986 . Among various tissues, the enzyme is most concentrated in the CNS (Minakuchi et al., 198 1) . Immunocytochemical and biochemical studies in this and other laboratories have revealed a differential regional and cellular localization of each PKC subspecies in the brain (Kitano et al., 1987; Hidaka et al., 1988; Huang et al., 1988; Kose et al., 1988; Saito et al., 1988 Saito et al., , 1989 Hosoda et al., 1989; Ito et al., 1990) . Particularly, the r-PKC subspecies is found only in the CNS (Ohno et al., 1987) .
Considerable numbers of phorbol ester binding sites, an indirect marker for PKC, were found in the striatonigral system (Worley et al., 1986) . Immunocytochemical studies also showed a specific localization of the PKC subspecies in the striatum and substantia nigra (SN; Huang et al., 1987; Saito et al., 1988 Saito et al., , 1989 . Furthermore, we noted a marked decrease in phorbol ester binding sites in the striatum from patients with Parkinson's disease (Nishino et al., 1989) or Huntington's disease (Kitamura et al., 1990) , a neurodegenerative disease of the nigrostriatal or striatonigral system, respectively. We now report detailed distributions of each PKC subspecies within the striatum and the SN and the colocalization with various neurotransmitters, findings that aid in elucidating the functions of each PKC subspecies in striatonigral and nigrostriatal systems.
Materials
and Methods Preparations of antibodies against PKC subspecies and various neurotransmitter markers. The rabbit antisera specific to the PKC subspecies were prepared against synthetic oligopepiides that correspond ;o the carboxvl-terminal nortion of each subsnecies (OFVHPILOSAV for the CX-PKC: SYTNPEI%INV for the PI-PK'C, and%VNSEFLKPEVKS for the BII-PKC, Hosoda et al., 1989; Saito et al., 1989; Ito et al., 1990) . The monoclonal antibody to r-PKC, obtained by immunizing mice with the purified PKC from the soluble fraction of rat brain, was characterized (Hashimoto et al., 1988) . The mouse polyclonal antisera specific to the o(-and @II-PKC were also obtained by immunizing mice with the same antigens used for the rabbit. Western blot analysis revealed that the antibodies reacted specifically with each subspecies.
The monoclonal antibody against GABA and the rabbit antiserum against GABA were raised and characterized, as described (Saito et al., 1986; Sakaue et al., 1989) .
The rabbit antisera against CAT and tyrosine hydroxylase (TH) were purchased from Chemicon and Eugene Tech International Inc., respectively.
Preparation of tissue sections. Male Wistar rats weighing 200 gm were separated into 3 groups: the first group was used as controls, the second group was given an intraventricular injection of colchicine (0.5 pcg/gm) 48 hr before perfusion, and the third group was treated with a unilateral intracerebral injection of 50 nM kainic acid (in 20 ~1 saline) given into the caudate-putamen (CP) 7 d before perfusion. The rats were anesthetized with an intraperitoneal injection of pentobarbital (50 mg/kg) and perfused through the left ventricle with saline, followed by fixatives. To obtain adequate staining of each antibody, 2 fixative solutions were prepared: fixative A, 0.5% glutaraldehyde, 4% paraformaldehyde, and 0.2% picric acid in 0.1 M phosphate buffer (pH, 7.0); and fixative B, periodate-lysine-paraformaldehyde fixative containing 0.05% pi& acid. Fixative A was suitable for the immunostaining of the PI-, pII-, and y-PKCs and GABA, and fixative B was proper for (u-PKC, TH, and CAT. After perfusion, the brain was removed from the cranial cavity, immersed in fixative A without glutaraldehyde or in fixative B, and kent in 30% sucrose in 0.1 M phosuhate buffer for several davs. The brains were then frozen and sectioned frontally at 20-pm thickness using a cryostat, for light microscopy. For electron microscopy, the brains were frozen in liquid nitrogen, thawed, and cut into 40-km-thick frontal sections on a vibratome.
Immunocytochemical procedures for the PKC subspecies. The PBS used here contained 0.03% Triton X-100 for light microscopic immunocytochemistry but not for electron microscopy. The sections were preincubated with 0.3% H,O, and 5% normal goat serum in PBS containing 0.03% Triton X-100 (PBS-T) to block the endogenous peroxidase activity and nonspecific binding ofthe antibodies. The preparations were subsequently incubated with primary antibodies at appropriate concentrations in PBS-T containing 5% normal goat serum for 18 hr at 4°C. After washing with PBS-T, the sections were incubated for an additional 4 hr with goat anti-mouse IgG (ICN, Lisle, IL) or goat antirabbit IgG (MBL, Nagoya, Japan), then were incubated for 1.5 hr with mouse peroxidase-antiperoxidase (PAP, ICN, Lisle, IL) complex or rabbit PAP complex (ICN, Lisle, IL). After 3 rinses, the preparations were developed with 0.02% 3,3'-diaminobenzidine (Sigma), 0.2% nickel ammonium sulfate. and 0.005% H,O, in 50 mM Tris-HCI (pH. 7.4). The sections were observed and photographed under a Zeiss light microscope.
For electron microscopy, the immunostained sections were washed in PBS, postfixed for 1 hr in 2% osmium tetroxide in 0.1 M PBS, dehydrated in a graded series of ethanol, and then flat embedded on siliconized slides in Epon. After polymerization at 60°C for 48 hr, the selected areas were cut off and attached to Epon supports for further sectioning on a Reichert-Jung Ultracut E ultramicrotome. Ultrathin sections were cut and mounted on 200-mesh uncoated grids (MAX-TAFORM). counterstained with 1% uranvl acetate in 50% ethanol, and examined with a JEM 1OOSX electron microscope.
Immunocytochemicalproceduresfor double labeling. We used doublelabeling methods to examine which transmitters coexist with each of the PKC subspecies. The sections for double labeling were first stained with antibody against one of the PKC subspecies by the PAP method, as described above. The stained sections already labeled with the dark purple products for the PKC subspecies were then incubated with antibodies to neurotransmitter markers (GABA, CAT, TH) or other PKC subspecies for 18 hr at 4°C followed by fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG or goat anti-mouse IgG Fab antibodies for 4 hr at room temperature. The sections were then mounted on slides with buffered glycerol for fluorescent or light microscopic observation.
Results

PKC-subspecies in the caudate-putamen and globus pallidus
Light and electron microscopic localization qf PKC subspecies As illustrated in Figure 1 , A and E, the antisera to cu-PKC labeled the large, scattered neurons (4045 Frn in diameter) in the CP and globus pallidus (GP). The immunoreactive neurons had a moderate immunoreaction in the perikaryal and proximal dendritic cytoplasm, and the perinuclear coarse, immunopositive dots were also seen in the perikarya. There was a diffuse immunoreactivity in the neuropils of the CP and a rather weak immunoreactivity in those of the GP. The fiber bundles were immunonegative.
The PI-PKC immunoreactivity was found in medium to large neurons (25-28 wrn in diameter) scattered evenly in the gray matter ofthe CP (Fig. l&F) . The immunoreactivity was present homogeneously in the periphery of the perikarya and in the proximal part of the dendrites. The neuropils and fiber bundles showed very weak immunoreactivity.
The @II-PKC immunoreactivity was seen in many mediumsized neurons (approximately 20 pm in diameter) throughout the CP and GP, predominantly in the caudal part. The immunoreactive products could be seen in a dotted pattern in the perinuclear area (Fig. 1 C,G) . The neuropils in both the CP and the GP showed intense immunoreactivity, which was more intense in the CP than in the GP. The fiber bundles were weakly immunopositive.
The y-PKC immunoreactivity was found in numerous medium-sized neurons (18-22 pm in diameter) scattered throughout the CP and GP. The immunoreactivity was dense in the perikarya and the proximal part of dendrites, but light in the nuclei (Fig. lD,H) . In addition, the immunoreaction was observed in the neuropils and fiber bundles. Electron microscopic analysis of the perikarya of the immunoreactive neurons for each PKC subspecies showed findings as follows: the (r-PKC immunoreactivity was present in the fringe of the perikaryon exhibiting the immunoreactive band along the plasma membrane, and small clusters of the immunoreaction were also scattered sparsely in the perinuclear area ( Fig. 2A) . The @I-PKC immunoreactivity was seen in the perikaryon just adjacent to the plasma membrane, and the fringe staining consisted of the clustered immunoreaction (Fig. 2B) . The PII-PKC immunoreactivity was observed in the cytoplasm is distributed in the scattered large neurons and the neuropils. The immunopositive neurons show a moderate immunoreaction along the perikaryal and proximal dendritic membrane and show dense immunopositive dots in the perikarya. Band F, The PI-PKC immunoreactivity is seen predominantly in the scattered medium to large neurons. The immunoreaction is present homogeneously within the perikarya and in the proximal part of the dendrites. C and G, The PII-PKC immunoreactivity is observed in the numerous medium-sized neurons and in the neuropils. The immunoreactive products could be seen in a dotted pattern in the perinuclear area. D and H, The r-PKC immunoreactivity is observed in many medium-sized neurons and the neuropils. The immunomaterials are dense in the perikarya and the proximal part of dendrites, but light in the nuclei. around the concave face (trans region) of the Golgi complex and on its membrane (Fig. 2C) . The r-PKC immunoreaction was dense throughout the pcrikaryal cytoplasm, except for the interior of the cell organelles, and light in the nucleoplasm (Fig.  20) .
Colocalization of the PKC subspecies and various neurotransmitter markers Double staining between 4 subspecies of PKC showed that no PKC subspecies coexisted with other PKC subspecies in the CP and GP. Even ,f311-PKC-and y-PKC-immunoreactive neurons, which were similar in size (approximately 20 Mm in diameter), did not overlap (Fig. 3) . The PII-PKC-immunoreactive neurons showed no T-PKC immunoreactivity, and the y-PKC-immunoreactive ones were not BII-PKC immunoreactive. Approximately 85% ofthe large cr-PKC-immunoreactive neurons showed CAT immunoreactivity, and all these immunoreactive neurons were (r-PKC immunoreactive (Fig. 4, Table 1 ). The PI-, @II-, and y-PKC-immunoreactive neurons contained no CAT immunoreactivity.
The antibody against GABA intensely labeled the scattered medium-sized neurons in the untreated rats. After colchicine treatment, additional medium-sized neurons were labeled with the same antibody. The CP contained 2 types of GABA-immunoreactive neurons that differed in size and staining properties: (1) neurons (25-28 pm in diameter) that exhibited intense GABA immunoreactivity in the rat striatum treated with or without colchicine, and (2) neurons (approximately 20 Frn in diameter) that displayed light GABA immunoreactivity only in the striatum treated with colchicine. Approximately 80% of the intensely GABA-immunoreactive neurons showed the PI-PKC immunoreactivity in the untreated rat striatum (Fig. 5 , Table  1 ). More than 90% of the lightly GABA-immunoreactive neurons exhibited immunoreactivity for PII-PKC in the striatum treated with colchicine (Fig. 6, Table 1 ). Only a small population (less than 10%) of the y-PKC-immunoreactive neurons displayed a weak immunoreaction for GABA (Fig. 7, Table 1 ) in the colchicine-treated but not untreated rats.
PKC subspecies in the substantia nigra Immunoreactivity of (u-PKC in the neuropils and in the large neurons mostly localized in the pars compacta was evident (Fig.  84 . The PI-PKC-immunoreactive neurons were scattered throughout the pars compacta and pars reticulata of the SN, but the neuropils showed very weak immunoreactivity (Fig. 8B) . Both the (Y-and PI-PKC immunoreactivities were localized along the cellular membrane. In contrast to the (Y-and PI-PKC, both the pII-and the y-PKC were abundantly present in the neuropils, which showed more intense immunoreactivity in the medial than in the lateral part of the pars reticulata, whereas neither labeled the neuronal perikarya (Fig. 8C,D) . Double-labeling methods revealed that more than 90% of the cu-PKC-immunoreactive cell bodies in the SN were immunoreactive for TH (Fig. 9, Table l) , while neither GABA nor TH was colocalized in the @I-PKC-immunoreactive cells (data not shown).
To elucidate the neuronal connection between the immunoreactive neurons in the CP and the immunoreactive neuropils in the SN, we examined the change of immunoreactivities for the PKC subspecies and neurotransmitter markers in the SN after unilateral injection of kainic acid into the head of the CP. The PII-and y-PKC immunoreactivities showed marked decreases on the injected side. The pII-PKC immunoreaction in the neuropils almost disappeared, while the -r-PKC immunoreaction in the neuropils partly disappeared but remained in the medial part of the pars reticulata. For (Y-and @I-PKC, no significant difference of the immunoreactivity was seen between control and injected sides (Fig. 10) .
Control study
Immunostaining for the PKC subspecies and neurotransmitter markers was abolished by substitution of preimmunized rabbit or mouse serum for each primary antiserum or by preadsorption of the primary antiserum with the respective antigen.
For double staining, sections that served as controls for the second step consistently failed to display FITC-labeled neurons, demonstrating (1) that the residual HRP from the first labeling step fails to react with the second chromogen, and (2) that there is little species cross-reactivity between the pairs of linking antiserum. 
Discussion
We obtained evidence that each subspecies of PKC showed a distinct distribution in the striatum and in the SN of the rat. Neostriatal neurons can be classified into several populations, based on size and dendritic cytoarchitecture, and also divided into several groups, immunocytochemically, by their neurotransmitter markers. The neuronal network between the neostriatum and the SN has to some extent been elucidated in immunohistochemical studies and by using tracing techniques. The majority of neostriatal neurons (70%) are medium-sized spiny cells that account for most of the neurons projecting to the SN. The medium-sized aspiny type, large spiny type, large aspiny type, and small type make up the remainder (Chang et al., 1982; Heimer et al., 1985) .
The localization of cu-PKC in the CAT-immunoreactive large neurons in the CP suggests that a-PKC is involved in certain functions of intrinsic cholinergic neurons. In the SN, the a-PKC immunoreactivity was localized in dopaminergic neurons projecting to the striatum. These findings are consistent with reports that CAT could be phosphorylated by PKC (Bruce and Hersh, 1989) and that TH is one of substrates of PKC (Albert et al., 1984; Nishizuka, 1986; Onali and Olianas, 1987) . In addition, a-PKC may modulate the membrane responsiveness of these neurons, related to the receptors and channels, because a-PKC was present predominantly along the perikaryal membrane within both the CP and the SN.
Resembling a-PKC, the BI-PKC immunoreactivity was predominant in the neuronal cell bodies rather than the neuropils. In the CP, most of the @I-PKC-immunoreactive neurons contained GABA in the rat treated with or without colchicine, observations that suggest that PI-PKC may play a specific functional role in intrinsic GABAergic neurons. It remains to be clarified which transmitters are contained in the PI-PKC-immunoreactive neurons scattered throughout the pars compacta and reticulata in the SN. The localization of PI-PKC along the cellular membrane in both regions does suggest that this subspecies is associated with the membrane responsiveness in the intrinsic GABAergic neurons.
In contrast, the @I-and y-PKC immunoreactivities showed different characteristics from (Y-and PI-PKC: (1) The PII-and y-PKC immunoreactivities were distributed not only in the numerous medium-sized neurons, but also in the neuropils in the CP and GP; (2) in the SN, the neuropils displayed intense immunoreactivity for @II-and r-PKC, but there were no immunoreactive cell bodies; and (3) the immunoreactivity in the neuropils of the ipsilateral SN was decreased in the rats treated with kainic acid, a compound that selectively destroys neuronal cell bodies. These findings suggest that the BII-and -/-PKC immunoreactivities in the SN are present in the afferent fibers from the striatum to the SN. Worley et al. (1986) lesioned with quinolinic acid. The present finding suggests that PII-or y-PIE may participate in the decrease in phorbol ester binding sites. Three neuroactive substances, GABA, substance P, and dynorphin, have been found in the rat striatonigral pathway (Vincent et al., 1982; Bolam et al., 1983; Heimer et al., 1985) . Double-staining methods revealed that the PII-PKC immunoreactivity was colocalized in more than 90% ofthe neurons labeled for GABA after colchicine treatment, while r-PKC was colocalized only with very few GABAergic neurons. It is likely that pII-PKC is contained within the striatonigral GABAergic neurons but that most of the y-PKC is related to other striaton&al neurons. There is some evidence that PKC modulates the depolarization-induced release of GABA from the rabbit caudate nucleus (Bartmann et al., 1989) and the KCl-evoked release of GABA from mouse striatal neurons (Weiss et al., 1989) . The pI-PKC in the intrinsic GABAergic neurons might be related to the release of GABA from the striatum. On the other hand, in the CP, the PII-PKC immunoreaction is remarkably greater than the @I-PKC immunoreaction in the neuropils. It may be that the release of GABA from the striatal slices includes the release from the axon collaterals of the medium-sized GABAergic neurons, which show ,f311-PKC immunoreactivity. This idea is supported by the finding that the axon collaterals of medium-sized spiny neurons form synaptic junctions with somata, initial segments of axons, dendrites, and dendritic spines of the striatal neurons (Wilson and Groves, 1980) . In addition, we found that the activation of PKC by 12-O-tetradecanoylphorbol-13-acetate enhanced the KCl-evoked release of endogenous GABA from SN slices (K. Taniyama et al., unpublished data) . It is suggested that BII-PKC is involved in the release of GABA in the SN.
There are reports that PKC participates in the release of ACh from striatal slices (Tanaka et al., 1986; Cubeddu et al., 1989) and in the release of dopamine from rat striatal synaptosomes (Chandler and Leslie, 1989) . Because (u-PKC immunoreactivity was present in the choline@ and dopaminergic cell bodies, it may be involved in the release of these neurotransmitters. Little cu-PKC immunoreaction was found in the neuropils of the CP, which contains abundant cholinergic and dopaminergic terminals. It is likely that the a-PKC in the nerve terminals is too low in density to be visualized in brain tissues treated with conventional fixatives for immunohistochemistry. It is also possible that yet to be identified PKC subspecies are involved in the release of ACh and dopamine. Nishino et al. (1989) found that, in tissues from patients with Parkinson's disease, the phorbol ester binding showed a significant reduction in the SN (by about 60%), CP (by about 40°h), and GP (by about 40%). The reduction in the phorbol ester binding in the SN may be attributed to both decreased (u-PKC in dopaminergic neurons and decreased BII-PKC in the GABAergic nerve terminals due to the transsynaptic degeneration of striatal neurons.
In patients with Huntington's disease, there are decreases in several neurotransmitters, including those of GABA, ACh, substance P, and methionine-enkephalin present within the striaton&al pathway. In contrast, dopamine, glutamate, and somatostatin are either not altered or are slightly increased. The concentrations of GABA are decreased 60% in the SN, CP, and GP, and there is a 50% reduction in CAT activity in the CP, while the concentration of substance P is markedly reduced in the striatopallidal (medial pallidurn) and striatonigral (pars reticulata) pathways. Pathological changes were predominant in medium-sized spiny neurons, but abnormalities in the mediumsized aspiny and large aspiny neurons were rare (Martin, 1984; Beal and Martin, 1986) . The reduction of phorbol ester binding in the striatum and the SN from patients with Huntington's disease may possibly be related to decreases in PII-or T-PKC rather than PI-and LU-PKC.
All these observations suggest that each PKC subspecies has an individual role in the striatal and nigral neurons: (r-PKC may play a role in regulating the membrane responsiveness in the striatal cholinergic and the nigral dopaminergic neurons, @I-PKC may be also involved in the membrane responsiveness in the striatal intrinsic GABAergic neurons, @II-and r-PKC are more likely to be related to functions mainly in the striatonigral
